Ascendis Pharma A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASND research report →
Companyascendispharma.com
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.
- CEO
- Jan Moller Mikkelsen
- IPO
- 2015
- Employees
- 1,017
- HQ
- Hellerup, DK
Price Chart
Valuation
- Market Cap
- $14.86B
- P/E
- 25.18
- P/S
- 14.73
- P/B
- 26.11
- EV/EBITDA
- -1886.95
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 88.17%
- Op Margin
- -0.80%
- Net Margin
- 58.40%
- ROE
- -5641.90%
- ROIC
- 1.51%
Growth & Income
- Revenue
- $691.71M · 90.22%
- Net Income
- $-219,034,140 · 42.07%
- EPS
- $-3.62 · 44.56%
- Op Income
- $-130,892,766
- FCF YoY
- 114.18%
Performance & Tape
- 52W High
- $250.74
- 52W Low
- $153.49
- 50D MA
- $231.74
- 200D MA
- $214.39
- Beta
- 0.41
- Avg Volume
- 678.89K
Get TickerSpark's AI analysis on ASND
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | JENSEN FLEMMING STEEN | sell | 19,460 |
| Mar 23, 26 | BIENAIME JEAN JACQUES | other | 0 |
| Mar 23, 26 | BIENAIME JEAN JACQUES | other | 9,160 |
| Mar 18, 26 | Fairey William | other | 0 |
| Mar 18, 26 | Fairey William | other | 9,160 |
| Mar 18, 26 | Fairey William | other | 1,930 |
| Mar 18, 26 | IMANI SIHAM | other | 0 |
| Mar 18, 26 | IMANI SIHAM | other | 9,160 |
| Mar 18, 26 | IMANI SIHAM | other | 1,930 |
| Mar 18, 26 | SMITH SCOTT THOMAS | other | 0 |
Our ASND Coverage
We haven't published any research on ASND yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ASND Report →